Trial Profile
Vaccination With PD-L1 Peptide With Montanide Against Multiple Myeloma After High Dose Chemotherapy With Stem Cell Support. A Phase I First-in-human Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs IO-103 (Primary) ; Montanide ISA-51
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- 30 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2018 New trial record